By Puyaan Singh and Christy Santhosh April 30 (Reuters) - Companies developing cannabis-based medicines say U.S. moves to ...

DOJ moves medical cannabis to Schedule III; biotech firms eye funding and IPOs amid banking and tax uncertainty.

A controversial federal shift is reshaping cannabis taxes, boosting some medical-only operators while complicating life for ...

Scientists have uncovered a surprising new layer of complexity in Cannabis, identifying dozens of previously unknown compounds—including the first-ever evidence of rare molecules called flavoalkaloids ...

The federal government’s reclassification of medical marijuana products as Schedule III drugs doesn’t federally legalize marijuana, but it might extend tax breaks to some cannabis businesses. The ...

Thousands of homes are being built using plant-based materials that experts say could help reduce carbon emissions in the ...

Is vaping weed healthier than smoking it? We unpack some benefits, the known harms, and a few unsettling questions sitting ...

The iconic High Times Cannabis Cup competition heads to Atlantic City as New Jersey’s legal cannabis market gains momentum ...

How big is the Black-owned cannabis market? The legal cannabis industry generates billions of dollars annually—reaching an ...

Nebraska’s medical cannabis laws could soon be protected from federal interference after all, under a proposed U.S. House ...